nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2008 | Original Paper

Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma

verfasst von: XueLi Bai, LiHua Wu, TingBo Liang, ZhiQiang Liu, JunJian Li, DongLin Li, HaiYang Xie, ShengYong Yin, Jun Yu, Qi Lin, ShuSen Zheng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It has been indicated that activated hepatic stellate cells (HSCs) play key roles on the pathogenesis of hepatocellular carcinoma (HCC). The purpose of the study was to investigate the potential mechanism in it.

Methods

Activation of HSCs, the expression of myocyte enhancer factor 2 (MEF2), class II histone deacetylases (II HDACs) and histone acetylation were analyzed in specimens of primary HCCs, cirrhotic and normal livers. Activated HSCs were identified using anti-a-smooth muscle actin (a-SMA) by Immunohistochemistry (IHC). The levels of expression of MEF2A, MEF2C and II HDACs mRNA and protein were measured by real time quantitative PCR and western blot (WB). Histone acetylation was assessed using anti-acetyl-histone H3, -H4 by WB and IHC. A P value < 0.05 was considered statistically significant.

Results

A-SMA positive activated HSCs were more prominent in HCCs and cirrhotic livers than in normal livers, accompanied by marked expression of MEF2A and MEF2C. The expression of MEF2A, MEF2C and II HDACs, both mRNA and protein, were much more enhanced in HCCs than those in cirrhotic and normal livers (P < 0.05). Histone H3 and H4 were hyperacetylated in HCCs compared with those in cirrhotic and normal livers (P < 0.05). The correlation coefficients between the expression of MEF2 and II HDACs, acetyl-histones were all beyond 0.5.

Conclusions

These data showed a potential molecular mechanism that activated HSCs participate in the pathogenesis of HCCs by overexpression of MEF2 and its consequent impact on histone hyperacetylation. Further investigations aimed at interfering MEF2 expression are needed.

Archer SY, Hodin RA (1999) Histone acetylation and cancer. Curr Opin Genet Dev 9:171–174PubMedCrossRef

Black BL, Olson EN (1998) Transcriptional control of muscle development by myocyte enhancer factor-2(MEF2) proteins. Annu Rev Cell Dev Biol 14:167–196PubMedCrossRef

Borghi S, Molinari S, Razzini G, Parise F, Battini R, Ferrari S (2001) The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci 114:4477–4483PubMed

Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601PubMedCrossRef

Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC et al (2005) Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci 102:3389–3394PubMedCrossRef

Clayton AL, Hazzalin CA, Mahadevan LC (2006) Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 23:289–296PubMedCrossRef

Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48:509–517PubMedCrossRef

Forner A, Hessheimer AJ, Isabel Real M, Bruix J (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89–98PubMedCrossRef

Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21:311–335PubMedCrossRef

Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H et al (2006) A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25:3170–3185PubMedCrossRef

Gruffat H, Manet E, Sergeant A (2002) MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep 3:141–146PubMedCrossRef

Han A, He J, Wu Y, Liu JO, Chen L (2005) Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 345:91–102PubMedCrossRef

Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE (1997) Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341–347PubMedCrossRef

Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401PubMedCrossRef

Kang J, Zhang D, Chen J, Lin C, Liu Q (2004) Involvement of histone hypoacetylation in Ni²⁺-induced bcl- 2 down-regulation and human hepatoma cell apoptosis. J Biol Inorg Chem 9:713–723PubMedCrossRef

Kang J, Chen J, Shi Y, Jia J, Wang Z (2005a) Histone hypoacetylation is involved in 1,10-phenanthroline-Cu²⁺-induced human hepatoma cell apoptosis. J Biol Inorg Chem 10:190–198PubMedCrossRef

Kang J, Chen J, Shi Y, Jia J, Zhang Y (2005b) Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem Pharmacol 69:1205–1213PubMedCrossRef

Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7:437–443PubMedCrossRef

Kim H, Lee JE, Kim BY, Cho EJ, Kim ST, Youn HD (2005) Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. Exp Mol Med 37:466–475PubMed

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S et al (1998) Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4:844–847PubMedCrossRef

Kurdistani SK, Tavazoie S, Grunstein M (2004) Mapping global histone acetylation patterns to gene expression. Cell 117:721–733PubMedCrossRef

Liang T, Xu S, Yu J, Shen K, Li D, Zheng S (2005) Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transplant 11:1527–1532CrossRef

Lin Q, Schwarz J, Bucana C, Olson EN (1997) Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276:1404–1407PubMedCrossRef

Ma K, Chan JK, Zhu G, Wu Z (2005) Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol Cell Biol 25:3575–3582PubMedCrossRef

Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286:785–790PubMedCrossRef

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202PubMedCrossRef

McKinsey TA, Zhang CL, Olson EN (2001) Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 11:497–504PubMedCrossRef

McLaughlin F, La Thangue NB (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68:1139–1144PubMedCrossRef

Mikula M, Proell V, Fischer AN, Mikulits W (2006) Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 209:560–567PubMedCrossRef

Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRef

Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumor stroma in cancer. Nat Rev Cancer 4:839–849PubMedCrossRef

Naya FJ, Olson E (1999) MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr Opin Cell Biol 11:683–688PubMedCrossRef

Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA, Hill JA, Olson EN (2002) Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 8:1303–1309PubMedCrossRef

Ooi LP, Crawford DH, Gotley DC, Clouston AD, Strong RW, Gobe GC et al (1997) Evidence that “myofibroblast-like” cells are the cellular source of capsular collagen in hepatocellular carcinoma. J Hepatol 26:798–807PubMedCrossRef

Park YN, Yang CP, Cubukcu O, Thung SN, Theise ND (1997) Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 17:271–274PubMed

Pinzani M, Rombouts K, Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42(Suppl 1):S22–S36PubMedCrossRef

Santos-Rosa H, Caldas C (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41:2381–2402PubMedCrossRef

Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK et al (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266PubMedCrossRef

Taddei A, Roche D, Bickmore WA, Almouzni G (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6:520–524PubMedCrossRef

Tokusashi Y, Asai K, Tamakawa S, Yamamoto M, Yoshie M, Yaginuma Y et al (2005) Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer 114:39–45PubMedCrossRef

Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z (2004) Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology 127:1174–1188PubMedCrossRef

Wen J, Zhang Y, Chen X, Shen L, Li GC, Xu M (2004) Enhancement of diallyl disulfide-induced apoptosis by inhibitors of MAPKs in human HepG2 hepatoma cells. Biochem Pharmacol 68:323–331PubMedCrossRef

Witz IP, Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1–10PubMedCrossRef

Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y (1996) A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319–324PubMedCrossRef

Titel: Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma
verfasst von: XueLi Bai
LiHua Wu
TingBo Liang
ZhiQiang Liu
JunJian Li
DongLin Li
HaiYang Xie
ShengYong Yin
Jun Yu
Qi Lin
ShuSen Zheng
Publikationsdatum: 01.01.2008
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0252-7

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials

Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study

An increase in cell number at completion of therapy may develop as an indicator of early relapse

Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats

An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie